NurExone Biologic Inc. presented preclinical data at the ARVO annual meeting, demonstrating that its ExoPTEN therapy restored retinal activity...

Corvus Pharmaceuticals released interim Phase 1 data for soquelitinib, an oral ITK inhibitor, in patients with moderate to severe...

UTRx Inc. submitted an Investigational New Drug (IND) application to the FDA for UTRxM1-18, a novel therapeutic targeting c-MYC...

Kriya Therapeutics presented preclinical data at the ARVO Annual Meeting for KRIYA-825, a gene therapy candidate for Geographic Atrophy...

Spherix Global Insights’ analysis of over 2,300 patient charts reveals a global shift in IgA nephropathy (IgAN) treatment, driven...

Yamo Pharmaceuticals announced positive Phase 2 trial results for L1-79, a drug targeting core autism spectrum disorder (ASD) symptoms,...

PDS Biotechnology Corporation announced preclinical data on its investigational Infectimune®-based flu vaccine at the IMMUNOLOGY2025™ Annual Meeting. Studies conducted...

Cognition Therapeutics announced topline results from its Phase 2 MAGNIFY trial of zervimesine, an oral drug for geographic atrophy...

Ashvattha Therapeutics announced positive interim Phase 2 results for its subcutaneously administered nanomedicine, migaldendranib (MGB), designed to treat retinal...

A real-world study published in JCO Precision Oncology suggests that Myriad Genetics’ RiskScore tool, integrated into its MyRisk Hereditary...